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BACKGROUND. The current study evaluated the effect of bevacizumab added to
fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver me-
tastases (CLM) on the pathologic response and nontumorous liver histology.
METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX
chemotherapy with (n 5 62) or without (n 5 43) bevacizumab were analyzed.
The response to chemotherapy was evaluated by pathologic analysis of tumor vi-
ability (percentage of viable tumor in relation to tumor surface area). The inci-
dence and grade of hepatic sinusoidal dilation were also investigated.
RESULTS. Bevacizumab-containing regimens significantly reduced the degree of
tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P
5 .02). After stratification according to the magnitude of tumor viability, a higher
proportion of patients treated with bevacizumab than without had <25% residual
viable tumor cells (45% vs 23%; P 5 .02). However, the addition of bevacizumab
to 5FU/OX did not appear to increase the incidence of complete pathologic
response (11.3% vs 11.6%; P 5 .59). The incidence and severity of sinusoidal dila-
tion was lower in patients treated with bevacizumab than in those treated with
5FU/OX only (any grade: 27.4% vs 53.5%; moderate or severe: 8.1% vs 27.9%;
both P < .01).
CONCLUSIONS. In patients treated with 5FU/OX chemotherapy, bevacizumab
improves the pathologic response, as demonstrated by a reduction of the degree
of tumor viability, and reduces the incidence and severity of hepatic injury. This
retrospective study provides additional evidence supporting the use of bevacizu-
mab in combination with 5FU/OX for CLM. Cancer 2007;110:2761–7.  2007
American Cancer Society.
KEYWORDS: oxaliplatin, bevacizumab, tumor response, colorectal liver metasta-
ses, sinusoidal dilatation, hepatotoxicity.
I n recent years, preoperative systemic chemotherapy has been usedin patients with colorectal liver metastases (CLM) to downsize
unresectable tumors and make hepatic resection possible,1–3 and to
identify responders so that patients can be spared nonbeneficial sur-
gical treatment and ineffective postoperative chemotherapy.4–6 The
clinical relevance of the radiographic response to chemotherapy,
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defined as a reduction of tumor size, is also empha-
sized by its conventional use for treatment efficacy
assessment.7 However, this simple, macroscopic cri-
terion for tumor response evaluation may not be
enough per se to determine the effectiveness of a
treatment.8 Pathologic analysis of tumor viability
represents an alternative method to evaluate tumor
response after preoperative treatments. Recent data
indicate that preoperative chemotherapy results in a
reduction or disappearance of viable tumor cells,9 and
assessment of residual viable tumor cells has been
used to compare the efficacy of different preoperative
treatments.10
As more patients receive preoperative systemic
chemotherapy, clinically significant chemotherapy-
specific hepatic injuries are increasingly being
reported.4,11–13 We recently reported a 20% incidence
of steatohepatitis in association with irinotecan-based
chemotherapy and a 19% incidence of sinusoidal
injury after treatment with oxaliplatin.4 In 2 series
reporting on patients who received mostly oxalipla-
tin-based preoperative chemotherapy, the authors
reported a higher rate of sinusoidal injury and an
increase in perioperative blood transfusions and sur-
gical complications in patients who received preo-
perative chemotherapy than in those who did not.11,12
In patients with advanced metastatic colorectal
cancer, targeted biologic therapy with bevacizumab, a
recombinant human monoclonal antibody to vascular
endothelial growth factor-A (VEGF-A), has recently
been used in association with 5-fluorouracil, irinote-
can, and oxaliplatin. Preliminary data from these stu-
dies indicate an increase in radiologic response rate
and survival with the combination of bevacizumab
and cytotoxic chemotherapy.14–16 However, to our
knowledge, the efficacy of bevacizumab in combina-
tion with chemotherapy in patients undergoing preo-
perative chemotherapy followed by liver resection has
not been published to date, and it is not known
whether the combination of bevacizumab and cyto-
toxic therapy improves pathologic response or affects
hepatic injury of the nontumorous liver.4,11
The objective of the current study was to deter-
mine the effect of bevacizumab added to fluoropyri-
midine-plus-oxaliplatin chemotherapy administered
before hepatic resection for CLM. To achieve this
objective, we reviewed a consecutive series of
patients who received preoperative fluoropyrimidine-
plus-oxaliplatin chemotherapy with or without beva-
cizumab to answer the following questions: Does
bevacizumab 1) increase the response of CLM as
measured by systematic pathologic analysis of tumor
viability? and 2) affect the incidence of sinusoidal
dilation?
MATERIALS AND METHODS
From the hepatobiliary database of the University
of Texas M. D. Anderson Cancer Center, we identi-
fied 105 consecutive patients who underwent liver
resection for CLM after preoperative fluoropyrimi-
dine-plus-oxaliplatin (5FU/OX) chemotherapy with
or without bevacizumab between November 2002
and July 2006. In the group that received bevacizu-
mab, the last dose was administered 6 or more
weeks before surgery.17 With the aim of maximizing
tumor response, 1 additional cycle of 5FU/OX was
usually administered after bevacizumab was dis-
continued. To ensure homogeneity within groups,
patients treated at any time before hepatic resec-
tion with drugs other than fluoropyrimidines, oxali-
platin, and bevacizumab were excluded. This study
was approved by our Institutional Review Board
(IRB #RCR06-0712).
Demographic and clinical data were obtained
by reviewing medical records. A single gastrointesti-
nal pathologist with hepatobiliary expertise (H.W.),
blinded to the chemotherapy regimens with which
individual patients had been treated, evaluated the
resected specimens. Nontumorous liver tissue was
reviewed to define the presence and grade of sinu-
soidal dilation according to a previously reported
standard 4-point scale on which 0 indicated the ab-
sence of sinusoidal dilation, 1 indicated mild sinu-
soidal dilation (centrilobular involvement limited to
approximately one-third of the lobular surface), 2
indicated moderate sinusoidal dilation (centrilob-
ular involvement extending in approximately two-
thirds of the lobular surface), and 3 indicated
severe sinusoidal dilation (complete lobular invol-
vement).4,18 The tumoricidal effect of chemoth-
erapy was analyzed using a previously defined
methodology19 as follows. On routine hematoxylin
& eosin-stained sections the area of residual viable
tumor cells within each metastatic nodule was esti-
mated as a percentage of the total tumor surface
area that includes areas of coagulative necrosis,
calcification, fibrosis, and the associated histio-
cytes, foreign body giant cells, and inflammatory
cells (Fig. 1). All archival slides, for an average of
2 to 3 sections per tumor nodule, were reviewed.
When multiple tumors were present, the mean
percentage was used.
Continuous variables, presented as means with
standard error of the mean unless otherwise stated,
were compared using the Mann-Whitney U test; dis-
crete variables, expressed as the number and per-
centage, were compared using the chi-square test or
Fisher exact test, when appropriate. Statistical signifi-
cance was defined as P < .05.
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RESULTS
Forty-three patients received 5FU/OX without bevaci-
zumab and 62 received 5FU/OX with bevacizumab.
Clinical and pathologic characteristics for the
patients in the 2 study groups are shown in Table 1.
Pathologic Response
A total of 285 tumor nodules were reviewed. Pathologic
analysis revealed that treatment with 5FU/OX only
was associated with significantly greater percentage of
residual viable tumor cells compared with treatment
with 5FU/OX plus bevacizumab (45.3%  3.7 vs 32.9%
 3.5; P 5 .02) (Fig. 2A). When patients were stratified
according to the magnitude of tumor viability (<25%,
25–49%, 50–75%, and >75% of total tumor surface
area), a significantly higher proportion of patients
treated with bevacizumab had <25% residual viable
tumor cells compared with patients who were not trea-
ted with bevacizumab (45% vs 23%; P 5 .02). A com-
plete pathologic response (ie, no identifiable viable
tumor cells in any tumor nodules) was observed in 5
patients (11.6%) treated with 5FU/OX only for a me-
dian of 12 cycles (range, 4–15 cycles) and 7 patients
(11.3%) treated with 5FU/OX plus bevacizumab for a
median of 4 cycles (range, 4–12 cycles) (P 5 .59). It is
FIGURE 1. Representative photomicrographs of metastases demonstrating
different percentages of residual viable tumor cells. (A) Approximately 90%
residual viable tumor cells. (B) Approximately 50% residual viable tumor
cells. (C) Extensive fibrosis, necrosis, calcifications, and the associated col-
lections of histiocytes and inflammatory cells with 1% viable tumor cells
(marked with arrows and shown in the inset ) (H & E, original magnification
320; inset: 3200).
TABLE 1
Clinical and Pathologic Features of Patients*
Variable
5FU/OX
(n = 43)
5FU/OX plus
bevacizumab
(n = 62) P
Median age (range), y 57 (26–80) 53.5 (34–85) .61
Gender
Male 26 (60) 36 (58) .80
Female 17 (40) 26 (42)
BMI
Median (range), kg/m2 27.1 (14.7–38.3) 27.5 (17.9–50.7) .89
>25 kg/m2 31 (72) 37 (60)
Coexisting diabetes 4 (9) 8 (13) .98
Site of primary tumor
Colon 32 (74) 43 (69) .57
Rectum 11 (26) 19 (31)
Status of primary lymph nodes
Positive 32 (74) 44 (71) .95
Not available 2 (5) 6 (10)
Synchronous hepatic metastasesy 32 (74) 34 (55) .12
Median no. of cycles of preoperative
chemotherapy (range) 6 (2–16) 6 (3–12)
.46
Mean (SEM) interval time between
completion of chemotherapy
and surgery, mo{ 1.71 (0.153) 1.99 (0.156) .15
Median largest tumor
dimension (range), cm§ 3.5 (1–10) 2 (0.5–12) .004
Colorectal liver metastases
Median no. (range) 2 (1–8) 2 (1–21) .33
Solitary metastasis 16 (37) 22 (35) .85
5FU/OX indicates fluoropyrimidines plus oxaliplatin; BMI, body mass index; SEM, standard error of
the mean.
* Values in the table are shown as the number of patients (percentages) unless otherwise indicated.
y Disease-free interval of <1 month.
{ Data were not available for all patients.
§ Calculated using the size of the largest lesion when multiple colorectal liver metastases were present.
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interesting to note that the mean dimension, mea-
sured on macroscopic pathology, of the 26 metastases
found in these 12 patients was 2 cm  0.5 cm (median,
1.9 cm) despite the absence of viable tumor cells.
There were a wide range of tumor sizes resected in
both groups (median, 2 cm [range, 0.5–12 cm] in the
bevacizumab group, and 3.5 cm [range, 1–10 cm] in
the 5FU/OX group). To investigate whether resected
tumor dimension might be associated with the degree
of pathologic response, patients were stratified accord-
ing to tumor dimension as measured on macroscopic
pathology for the following subgroups: 2 cm, 3 cm,
4 cm, and >4 cm (the number of patients compared
in each stratum were 40, 47, 54, and 8, respectively, in
the bevacizumab group and 16, 21, 28, and 15, respec-
tively, in the 5FU/OX group) (Fig. 2B).
Treatment with bevacizumab was associated
with significantly reduced percentages of residual
viable tumor cells in each subgroup (2 cm: 24.6%
 3.7 [median, 20%] vs 45.6%  6.6 [median, 50%] [P
5 .01]; 3 cm: 25.9%  3.7 [median, 20%] vs 46.2%
 5.2 [median, 50%] [P 5 .003]; and 4 cm: 29.5%
 3.5 [median, 30%] vs 45.4%  5.1 [median, 50%] [P
5 .01]). When considering patients with tumors >4
cm, no difference was found between patients trea-
ted with and those treated without bevacizumab
with regard to tumor viability (58.5%  10.7 [median,
70%] vs 45.3  5.3 [median, 50%]; P 5 .09).
Overall, treatment duration was similar between
the groups treated with and those treated without
bevacizumab. To clarify the effect of the duration of
chemotherapy on pathologic response, patients were
stratified according to the number of cycles of 5FU/
OX received (2–4 [42 patients], 5–8 43 patients]; and
>8 [20 patients]). The distribution of patients across
these subgroups was similar between the 2 treatment
groups (5FU/OX with or without bevacizumab).
Patients treated without bevacizumab had greater
percentages of residual viable tumor cells than those
treated with bevacizumab regardless of the duration
of treatment (2–4 cycles: 50%  5.3 [median, 50%] vs
35.5%  6.2 [median, 30%]; 5–8 cycles: 46.2%  5.9
[median, 55%] vs 32.7%  4.3 [median, 30%]; and >8
cycles: 32.5%  9.9 [median, 45%] vs 28.18%  9.2
[median, 5%], respectively) (differences did not reach
statistical significance in these subgroup analyses).
Incidence of Sinusoidal Dilation
Pathologic review of the nontumorous liver paren-
chyma revealed that the incidence of sinusoidal dila-
tion of any grade was significantly higher in patients
treated without bevacizumab (23 of 43 patients;
53.5%) than in those treated with bevacizumab (17 of
62 patients; 27.4%) (P 5 .006) (Fig. 3A). The incidence
of moderate or severe sinusoidal dilation was also
significantly higher in patients treated without beva-
cizumab (12 of 43 patients; 27.9%) than in those
treated with bevacizumab (5 of 62 patients; 8.1%)
(P 5 .006) (Fig. 3B). These differences were inde-
pendent of the duration of chemotherapy. The
median number of cycles of 5FU/OX was similar in
patients who developed any grade of sinusoidal dila-
tion (6 cycles; range, 2–16 cycles) and those who did
not (6 cycles; range, 2–15 cycles) and in those who
developed moderate to severe sinusoidal dilation (6.5
cycles; range, 2–13 cycles) and those who did not (6
cycles; range, 2–16 cycles) (both P > .05).
FIGURE 2. Percentage of residual tumor cells after preoperative chemo-
therapy with fluoropyrimidine plus oxaliplatin only (5FU/OX) and 5FU/OX plus
bevacizumab (5FU/OX plus Bev). (A) Overall results. (B) Results for subgroups
stratified according to posttreatment tumor dimension as measured on mac-
roscopic pathology. *P < .05.
FIGURE 3. Incidence of (A) sinusoidal dilation of any grade and (B) moder-
ate or severe (grade 2 or 3) sinusoidal dilation after preoperative chemother-
apy with fluoropyrimidines plus oxaliplatin only (5FU/OX) or 5FU/OX plus
bevacizumab (5FU/OX plus Bev). *P 5 .006.
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DISCUSSION
In this study, we found that 5FU/OX plus bevacizu-
mab was oncologically more effective than 5FU/OX
alone as demonstrated by the greater pathologic
responses assessed in resected tumors. We also
found that the incidences and severity of hepatic
injury were reduced when bevacizumab was added
to 5FU/OX. These findings provide additional evi-
dence supporting the use of bevacizumab for CLM.
To our knowledge, this is the first study to analyze
the pathologic effect of preoperative chemotherapy
with 5FU/OX plus bevacizumab on resected CLM and
nontumorous liver. Previous studies have examined
the efficacy of bevacizumab added to cytotoxic ther-
apy using clinical outcome measures,14,15 but analysis
of pathologic changes that occur in tumors after treat-
ment with biologic agents is lacking.
Our decision to evaluate tumor response patho-
logically was motivated by recent reports that suggest
that radiologic assessment of changes in tumor size
may not accurately reflect response to chemother-
apy8 and may either overestimate20 or underestimate
the actual extent of tumor regression.18 (Fig. 4) Two
studies focused on targeted biologic therapies have
further emphasized these limitations21 and demon-
strated that in some disease types changes in tumor
size in response to biologic therapies underestimate
the actual pathologic tumor response.22 One possible
explanation is that radiologic methods cannot fully
differentiate between areas of viable tumor and areas
of fibrotic replacement induced by effective chemo-
therapy. (Fig. 4)
A recent study by Rubbia-Brandt et al.9 provides
new insights into the pathologic changes induced by
oxaliplatin-based chemotherapy and provides a fra-
mework within which the findings of the current
study can be analyzed. The findings of that study
demonstrated that, compared with tumors not trea-
ted with preoperative chemotherapy, tumors treated
with preoperative oxaliplatin exhibit significant tu-
mor regression with marked reduction or disappear-
ance of viable tumor cells and fibrosis overgrowth.18
In the current study, we confirmed the finding of
Rubbia-Brandt et al. that tumor response to chemo-
therapy is characterized, in part, by replacement of
tumor with fibrosis (Fig. 1C). Furthermore, we found
not only that a similar pathologic change occurs in
tumors treated with 5FU/OX plus bevacizumab, but
the addition of bevacizumab to 5FU/OX yielded an
incrementally greater decrease in residual viable cells
within the resected tumors over the decrease asso-
ciated with 5FU/OX alone. It is interesting to note
that this differentially greater pathologic response
with bevacizumab was significant in tumors mea-
suring 4 cm and was independent of the duration
of chemotherapy. The absence of improved response
in tumors measuring >4 cm may be related to the
inadequate sample size to detect the difference, or to
the lesser effectiveness associated with bevacizumab
for this subset. These data also suggest that the
improved tumor regression with bevacizumab occurs
early during treatment and that a fairly stable benefit
is sustained with increasing duration of treatment.
Increased pathologic response to preoperative
treatment is associated with improved long-term out-
come in several malignancies, such as esophageal
cancer and colorectal cancer.19,23 A similar survival
FIGURE 4. Pathologic response to preoperative treatment with fluoropyri-
midines plus oxaliplatin (5FU/OX) and bevacizumab in a patient aged 36
years with synchronous bilobar liver metastases from pT3 pN1 sigmoid ade-
nocarcinoma who was a candidate for a 2-stage hepatectomy. (A) Before
chemotherapy, the patient had a metastasis measuring 3.4 cm in segment 3
of the liver. (B) Partial radiographic response of the metastasis in segment 3
after 3 cycles of 5FU/OX and bevacizumab (dimension of 1.5 cm). At this
time, the patient underwent wedge resection of the metastasis in segment 3
(first-stage surgery). A representative photomicrograph of this metastasis is
shown in Figure 1C.
Colorectal Liver Metastases and Bevacizumab/Ribero et al. 2765
advantage has been recently reported in patients
with CLM treated with 5-fluorouracil, oxaliplatin, or
irinotecan.9 However, whether the degree of im-
proved pathologic response associated with bevaci-
zumab for CLM translates into improved long-term
outcome remains to be evaluated by further study.
The second major finding of this study was that
bevacizumab reduced the incidence and severity of
oxaliplatin-related sinusoidal dilation. Oxaliplatin-
based chemotherapy has been shown to cause he-
patic sinusoidal dilation,4,12,18 a vascular injury char-
acteristic of veno-occlusive disease,24 recently
renamed sinusoidal obstruction syndrome (SOS).25
SOS is a complication of conditioning chemotherapy
before bone marrow transplantation in 5% to 54% of
patients.26–28 Although to our knowledge the patho-
physiology of drug-induced SOS is not fully under-
stood, in vitro and in vivo models suggest that
oxaliplatin induces an overproduction of reactive ox-
ygen species and depletion of glutathione in endo-
thelial cells,29,30 which plays a pivotal role in SOS
development.31 DeLeve et al.32 have also demon-
strated that sinusoidal endothelial cell release of
matrix metalloproteinase (MMP)-2 and MMP-9 preci-
pitates the early steps of SOS by degrading the extra-
cellular matrix in the spaces of Disse and endothelial
cell degradation and embolization. VEGF is known to
regulate MMP-9 activation by inducing its expres-
sion. In patients undergoing bone marrow transplan-
tation, the serum VEGF level is found to be elevated
in individuals who develop SOS, and the degree of
the increase in VEGF serum level parallels the clini-
cal severity of SOS.33 Therefore, although the
mechanisms that explain a bevacizumab-mediated
decrease in the hepatic toxicity of oxaliplatin remain
unknown, VEGF blockade may attenuate sinusoidal
injury by down-regulating MMP-9 production.
The clinical relevance of sinusoidal dilation with
respect to outcomes after hepatic resection is increas-
ingly recognized. We reported no increase in morbidity
after a median of 12 weeks of treatment with oxalipla-
tin-based chemotherapy,4 but 2 recent studies have
described an increase in blood transfusions and com-
plications in patients treated preoperatively for >12
weeks.11,12 In rare cases, prolonged treatment of CLM
with oxaliplatin has been associated with SOS and
death.13 Although our study cannot clarify whether
bevacizumab protects from long-term exposure to
oxaliplatin, the protective effect of bevacizumab
observed in the current study is attractive.
Although this study is limited by its retrospective
nature, the increase in the magnitude of pathologic
response after treatment with bevacizumab and the
reduction in the incidence and severity of sinusoidal
dilation strongly suggest a benefit for the use of bev-
acizumab-containing regimens over oxaliplatin alone.
Further studies are needed to expand on these initial
findings and to provide further insight into the role
of bevacizumab as a potentially protective agent
against the broader spectrum of diseases associated
with SOS.
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